TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2461826

Group type: EXPERIMENTAL
Intervention: Inhalation of adenosine 5'-monophosphate (AMP) at the provocation concentration required to produce a 20% fall in FEV1 (PC20)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhalation of 0.9% (w/v) sodium chloride placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhalation of the PC20 allergen
Number of subjects: 12
Study: 31814306

Group type: EXPERIMENTAL
Intervention: Delta-shaped anastomosis
Number of subjects: 39

Group type: COMPARATOR
Intervention: Circular stapler anastomosis
Number of subjects: 39
Study: 31465185

Group type: EXPERIMENTAL
Intervention: TegadermTM (Group T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TegadermTM with sticky pad (Group P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TegadermTM with Steri‐StripTM (Group S)
Number of subjects: 0
Study: 28730884

Group type: EXPERIMENTAL
Intervention: Financial compensation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no financial compensation)
Number of subjects: 0
Study: 25641932

Group type: EXPERIMENTAL
Intervention: Dry bean enriched diet (250 g/day) for 4 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Navy bean ethanol extract (10%) for 6 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Self-reported high dry bean intake (≥42 g/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Self-reported low dry bean consumption (<8 g/day)
Number of subjects: 46
Study: 23078515

Group type: EXPERIMENTAL
Intervention: Vitamin E (E)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pycnogenol (P)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Glycerine (control)
Number of subjects: 72
Study: 22043672

Group type: EXPERIMENTAL
Intervention: Acupoint catgut-embedding
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 60
Study: 19358978

Group type: EXPERIMENTAL
Intervention: Chronotherapeutic augmentation (CAT; Sleep Deprivation + Bright Light + Sleep Phase Advance)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Medication-only (MED) group
Number of subjects: 49
Study: 17109618

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 0
Study: 15279663

Group type: EXPERIMENTAL
Intervention: CMPD patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 35

Group type: COMPARATOR
Intervention: CMPD patients vs Control group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CMPD patients with marrow fibrosis
Number of subjects: 35
Study: 11716099

Group type: EXPERIMENTAL
Intervention: Paromomycin plus methylbenzethonium chloride ointment applied twice a day for 20 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Paromomycin plus methylbenzethonium chloride ointment
Number of subjects: 68
Study: 9136830

Group type: EXPERIMENTAL
Intervention: 30 pmol x kg(‐1) x h(‐1) of PYY
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 90 pmol x kg(‐1) x h(‐1) of PYY
Number of subjects: 6

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 6
Study: 7971101

Group type: EXPERIMENTAL
Intervention: Vertical axis of symmetry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Horizontal axis of symmetry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagonal axes of symmetry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Range of stimuli presented
Number of subjects: 0
Study: 3672087

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31930663

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic testing for aneuploidy (PGT-A) by polar body biopsy and array-based comprehensive genome hybridisation (aCGH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular IVF/ICSI without PGT-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic testing for aneuploidy (PGT-A)
Number of subjects: 0
Study: 30648920

Group type: EXPERIMENTAL
Intervention: Mobile wellness intervention with Fitbit, daily motivational text messaging, and biweekly counseling for 12 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Fitbit only
Number of subjects: 79
Study: 28275109

Group type: EXPERIMENTAL
Intervention: Graded Exercise (GE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (GE, IE, UC)
Number of subjects: 24
Study: 24403296

Group type: EXPERIMENTAL
Intervention: CBC risk score tertile 3
Number of subjects: 17197

Group type: EXPERIMENTAL
Intervention: CBC risk score tertile 2
Number of subjects: 17197

Group type: EXPERIMENTAL
Intervention: CBC risk score tertile 3 (after adjustment)
Number of subjects: 17197

Group type: EXPERIMENTAL
Intervention: CBC risk score tertile 2 (after adjustment)
Number of subjects: 17197

Group type: EXPERIMENTAL
Intervention: CBC risk score
Number of subjects: 17197
Study: 23124255

Group type: EXPERIMENTAL
Intervention: ProDisc-C (TDR)
Number of subjects: 209

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: TDR
Number of subjects: 209

Group type: COMPARATOR
Intervention: ACDF and TDR
Number of subjects: 209
Study: 20453699

Group type: EXPERIMENTAL
Intervention: Intraoperative blood products per kg (highest tertile)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Any blood products on postoperative day 1
Number of subjects: 270
Study: 18272844

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Losartan monotherapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-sodium diet + Losartan
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) + Losartan
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-sodium diet + HCT + Losartan
Number of subjects: 34
Study: 16946613

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement restorations (aged)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement restorations (unaged)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resin composite restorations (aged)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resin composite restorations (unaged)
Number of subjects: 16
Study: 14512149

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Brotizolam (0.25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10637406

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) applied to subjects with probable AD and depression
Number of subjects: 186

Group type: COMPARATOR
Intervention: Beck Depression Inventory (BDI) applied to subjects with probable AD without depression
Number of subjects: 186
Study: 9577009

Group type: EXPERIMENTAL
Intervention: Tolperisone HCL (Mydocalm) 150 mg twice daily for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tolperisone HCL (Mydocalm)
Number of subjects: 72
Study: 8449072

Group type: EXPERIMENTAL
Intervention: Buspirone (10 to 20 mg given three times a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3092311

Group type: EXPERIMENTAL
Intervention: IGIV pH 4.25
Number of subjects: 39

Group type: COMPARATOR
Intervention: IGIV pH 6.8
Number of subjects: 39
Study: 30005948

Group type: EXPERIMENTAL
Intervention: PCV7‐TT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Synflorix®
Number of subjects: 30
Study: 27284930

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg orally
Number of subjects: 8
Study: 24752831

Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS-25) 10 mg once daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS-25) 5, 10, and 20 mg (multiple ascending doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS-25) 1, 3, 5, 10, 20, and 30 mg (single ascending doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS-25)
Number of subjects: 0
Study: 22345094

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily added to losartan 100 mg once daily plus optimal antihypertensive therapy
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo added to losartan 100 mg once daily plus optimal antihypertensive therapy
Number of subjects: 599
Study: 20819472

Group type: EXPERIMENTAL
Intervention: Endoscopic turbinoplasty
Number of subjects: 150

Group type: COMPARATOR
Intervention: Laser-assisted turbinoplasty
Number of subjects: 150
Study: 17095135

Group type: EXPERIMENTAL
Intervention: Neonatal LMA-ProSeal (PLMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neonatal classic laryngeal mask airway (cLMA)
Number of subjects: 0
Study: 16378559

Group type: EXPERIMENTAL
Intervention: Care by GPwSIs in practices
Number of subjects: 321

Group type: COMPARATOR
Intervention: Care by GPwSIs in hospital outpatient departments
Number of subjects: 321
Study: 11923490

Group type: EXPERIMENTAL
Intervention: Undiluted smallpox vaccine (10^8.1 pfu/ml)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: 1:5 diluted smallpox vaccine (10^7.2 pfu/ml)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: 1:10 diluted smallpox vaccine (10^7.0 pfu/ml)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: All groups (undiluted and diluted vaccines)
Number of subjects: 680
Study: 9616521

Group type: EXPERIMENTAL
Intervention: Oxygen concentrators
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cylinders
Number of subjects: 26
Study: 8133536

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 4063

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4063

Group type: EXPERIMENTAL
Intervention: Tamoxifen (randomized group)
Number of subjects: 4063
Study: 2675299

Group type: EXPERIMENTAL
Intervention: Hemodilution therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study: 126848

Group type: EXPERIMENTAL
Intervention: Azapropazone (300 mg, 4-times daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketoprofen (50 mg, 4-times daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (intermediate period)
Number of subjects: 50
Study: 31356511

Group type: EXPERIMENTAL
Intervention: Barbell Hip Thrust (BHT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Back Squat (SQ)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Romanian Deadlift (RDL)
Number of subjects: 8
Study: 27840252

Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator (RC) for prostate cancer
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator (RC) for significant PCa
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator (RC) for unnecessary biopsies
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Variability of ERSPC risk calculator (RC)
Number of subjects: 749
Study: 26940016

Group type: EXPERIMENTAL
Intervention: Aerobic training (8-week program)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (daily routines)
Number of subjects: 29
Study: 25198082

Group type: EXPERIMENTAL
Intervention: Collagenase ointment (CO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 10
Study: 22143991

Group type: EXPERIMENTAL
Intervention: Double-balloon endoscopy (DBE)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Magnet-imaging enhanced colonoscopy with cap (MEI-Cap)
Number of subjects: 94
Study: 20179636

Group type: EXPERIMENTAL
Intervention: Oral beclomethasone dipropionate (BDP) 5 mg/day for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral 5-aminosalicylate (5‐ASA) 80 mg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 17394636

Group type: EXPERIMENTAL
Intervention: Education and activation program (EAP) administered by trained GPs.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (UC) administered by GPs.
Number of subjects: 10
Study: 16236947

Group type: EXPERIMENTAL
Intervention: Manual hyperinflation (MH) technique at a rate of 8 to 13 breaths/min for 20 min each session, three times per day for 5 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard prescribed mechanical ventilation without supplemental MH
Number of subjects: 23
Study: 11960957

Group type: EXPERIMENTAL
Intervention: Exercise at varying intensities (25% and 75% of the difference between lactate threshold and rest, at lactate threshold, and at 25% and 75% of the difference between lactate threshold and peak O2 uptake) for 30 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 8
Study: 10212618

Group type: EXPERIMENTAL
Intervention: Anteroinferior pin purchase with AO frame
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anteroinferior pin purchase with Orthofix
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anterosuperior pin purchase with AO frame
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anterosuperior pin purchase with Orthofix
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anteroinferior location of pin purchase
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dissection of preinserted anatomic specimen
Number of subjects: 5
Study: 7836337

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg once daily, titrated to a maximum of 200 mg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 113
Study: 1839437

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 74
Study: 6187544

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (24 hours)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Secobarbital-induced sleep
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Waking state
Number of subjects: 69
Study: 30729333

Group type: EXPERIMENTAL
Intervention: Vitamin D vaginal suppositories
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Vitamin E vaginal suppositories
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 30197282

Group type: EXPERIMENTAL
Intervention: Tdap-B
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Tdap-A
Number of subjects: 809

Group type: COMPARATOR
Intervention: Tdap-B and Tdap-A
Number of subjects: 809
Study: 26813753

Group type: EXPERIMENTAL
Intervention: Stirrup brace
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Walker boot
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tubigrip
Number of subjects: 18
Study: 27502042

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (PMVR)
Number of subjects: 58
Study: 23824645

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: capecitabine (1,000 mg/m2 twice daily, day 1-day 14)
Number of subjects: 52
Study: 22046601

Group type: EXPERIMENTAL
Intervention: Passive referral
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Contract referral
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Provider referral
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Returning partners (n = 107)
Number of subjects: 245
Study: 19844125

Group type: EXPERIMENTAL
Intervention: Omnitrope((R)) lyophilisate (group A, n = 44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Genotropin((R)) (group B, n = 45)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Omnitrope((R)) liquid
Number of subjects: 89

Group type: COMPARATOR
Intervention: Genotropin((R)) switched to Omnitrope((R)) liquid
Number of subjects: 89
Study: 17096182

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 14991587

Group type: EXPERIMENTAL
Intervention: Clear cell RCC
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chromophobe RCC
Number of subjects: 5
Study: 11699068

Group type: EXPERIMENTAL
Intervention: 100 micrograms of rhIFN-gamma subcutaneously (treated group, n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group, n = 22)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: rhIFN-gamma (treated group)
Number of subjects: 46
Study: 9043722

Group type: EXPERIMENTAL
Intervention: Group BAL (alfentanil/N2O)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Group INH (isoflurane/fentanyl/N2O)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Group TIVA (propofol/alfentanil/O2)
Number of subjects: 93
Study: 8551442

Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and trabeculotomy ab externo
Number of subjects: 106

Group type: COMPARATOR
Intervention: Phacoemulsification alone with IOL implantation
Number of subjects: 106
Study: 1699628

Group type: EXPERIMENTAL
Intervention: Cernilton (pollen extract) for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 368299

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.3 mg/kg at admission and a similar dose 2 hours later)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 30958325

Group type: EXPERIMENTAL
Intervention: Visual assessment using light microscopy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Digital image analysis from one central laboratory
Number of subjects: 27
Study: 28214392

Group type: EXPERIMENTAL
Intervention: RNC cigarette advertisement
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RNC cigarette use (0.6mg nicotine yield)
Number of subjects: 77
Study: 25587091

Group type: EXPERIMENTAL
Intervention: Discharge summaries completed on the day of discharge
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Documented transmission to the follow-up physician
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Content quality based on Transitions of Care Consensus Conference elements
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Inclusion of hospital course in discharge summaries
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Inclusion of discharge condition in discharge summaries
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Inclusion of discharge volume status in discharge summaries
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Inclusion of discharge weight in discharge summaries
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Overall quality of discharge summaries
Number of subjects: 1640
Study: 23719070

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 59
Study: 21333314

Group type: EXPERIMENTAL
Intervention: Oxandrolone treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 26
Study: 19589901

Group type: EXPERIMENTAL
Intervention: High intermittent dose of liposomal amphotericin B (10 mg kg(‐1) on day 1, 5 mg kg(‐1) on days 3 and 6)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard daily dose of liposomal amphotericin B (3 mg kg(‐1) per day for 14 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High intermittent dose of liposomal amphotericin B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard daily dose of liposomal amphotericin B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 60
Study: 17116219

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg (500 mg bid.) on the first treatment day, increased to 2000 mg (1000 mg bid.) from the second day onward.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 15589082

Group type: EXPERIMENTAL
Intervention: Self-care management strategies including prescribed medications for pain management (54.21% of participants used this strategy).
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Training nursing home staff to perform regular pain assessments and provide knowledge about pain assessment and management strategies.
Number of subjects: 150
Study: 11733289

Group type: EXPERIMENTAL
Intervention: BiPAP ventilation plus standard treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard treatment alone (non-BiPAP)
Number of subjects: 35
Study: 9164221

Group type: EXPERIMENTAL
Intervention: Higher-dose chemotherapy regimen with rhGM-CSF (cyclophosphamide 1,800 mg/m2, 4'-epidoxorubicin 60 mg/m2, etoposide 330 mg/m2, cisplatin 120 mg/m2, plus rhGM-CSF 5 micrograms/kg daily for 10 days)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy regimen (cyclophosphamide 1,200 mg/m2, 4'-epidoxorubicin 40 mg/m2, etoposide 225 mg/m2, cisplatin 100 mg/m2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher-dose plus rhGM-CSF group
Number of subjects: 125
Study: 8425987

Group type: EXPERIMENTAL
Intervention: Risk deciles 9 and 10
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Risk deciles 1 and 2
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Total study group
Number of subjects: 1612
Study: 2221511

Group type: EXPERIMENTAL
Intervention: Chloropromazine 12.5 mg IV (max 37.5 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dihydroergotamine 1 mg IV (repeated after 30 minutes if inadequate response)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lidocaine 50 mg IV (max total dose of 150 mg)
Number of subjects: 76
Study: 589919

Group type: EXPERIMENTAL
Intervention: Arachis oil emulsion
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Chocolate-Sorbitol preparation
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 46 g of milk chocolate
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 26 g of milk chocolate
Number of subjects: 450
Study: 31074333

Group type: EXPERIMENTAL
Intervention: Stratified randomization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted t test under misclassification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additive bias model combining selection bias and time‐trend bias
Number of subjects: 0
Study: 30332895

Group type: EXPERIMENTAL
Intervention: Memory Work Therapy
Number of subjects: 48
Study: 27786358

Group type: EXPERIMENTAL
Intervention: Calling the patient's name
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (general term)
Number of subjects: 101